WINNIPEG, MB, March 23, 2022 /PRNewswire/ – Medicure Inc. (“Medicine“or the”Company“) (TSXV: MPH) (OTC: MCUJF), a company focused on the development and commercialization of pharmaceutical and healthcare products for patients and prescribers in United States market, today announced that Chief Financial Officer david gurvey (CPA, CMA, B.Sc.) resigns, effective March 25, 2022.

Albert D. FriesenPhD, CEO and Chairman of the Board, said, “On behalf of everyone at Medicure and our Board of Directors, we thank David for his contribution to our company and wish him well in his future endeavours. .

The Company has launched the search for a new CFO with the capabilities and qualifications to accelerate Medicure’s growth and business strategy. dr. Neil OwensChief Operating Officer of the Company, will assume the role of Interim Chief Financial Officer upon the resignation of Mr. Gurvey.

About Medicine Inc.
Medicure is a pharmaceutical company focused on the development and commercialization of innovative and affordable therapeutic products for the US market. Medicure’s sales force targets physicians and other healthcare professionals and, through e-commerce integration, will offer patients and providers direct online ordering and home delivery. Our vision is to become a leading pharmaceutical company in the United States, offering a growing portfolio of products that improve the lives of patients. The company is currently focused on the marketing and distribution of AGGRASTAT® (tirofiban hydrochloride) injections and ZYPITAMAG® (pitavastatin) tablets in United Stateswhere they are sold through the Company’s US subsidiary, Medicure Pharma Inc. Medicure also operates Marley Drug®, Inc. (“Marley Drug”), a pharmacy located in North Carolina which offers an extended drug supply program serving all 50 states, washington d.c. and most territories, including Porto Rico. Marley Drug is committed to improving the health of its patients and the communities they serve while reducing overall health care costs for employers and other health care consumers. For more information, visit To learn more about the Extended Generic Drug Supply Program, call 800.286.6781 or email [email protected] For more information on Medicine, please visit For more information on AGGRASTAT®, see the complete prescribing information. For more information on ZYPITAMAG®, see the complete prescribing information.

To be added to the Medicure mailing list, please visit:

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-looking information: statements contained in this press release that are not statements of historical fact, including, without limitation, statements containing the words “believes”, “may”, “plans”, “will” , “estimates”, “continues”, “anticipates”, “intends”, “expects” and similar expressions, may constitute “forward-looking information” within the meaning of applicable Canadian and United States federal laws on securities (such forward-looking information and forward-looking statements are hereinafter collectively referred to as “forward-looking statements”). Forward-looking statements include estimates, analyzes and opinions of the Company’s management made in light of its experience and perception of trends, current conditions and expected developments, as well as other factors that the Company believes relevant and reasonable under the conditions. Forward-looking statements involve known and unknown risks, uncertainties and other factors that are beyond the Company’s ability to predict or control and that may cause actual results, events or developments to differ materially from the results, future events or developments expressed or implied by such forward-looking statements and, as such, readers are cautioned not to place undue reliance on any forward-looking statements. These risk factors include, among others, future revenue from the Company’s products, expected results, including future revenue from P5P, likelihood of receiving a VRP, expected future revenue growth, stage of development, additional capital requirements, the risks associated with the completion and timing of clinical trials and obtaining regulatory approval to commercialize the Company’s products, the ability to protect its intellectual property, dependence on – vis-à-vis collaboration partners, changes in government regulations or regulatory approval processes, and rapid technological changes in the industry. These statements are based on a number of assumptions which may prove to be incorrect, including, but not limited to, assumptions regarding: general business and economic conditions; the impact of fluctuations in the Canadian dollar against the US dollar and other foreign exchange rates on the Company’s revenues, costs and results; the timing of receipt of regulatory and governmental approvals for the Company’s research and development projects; the availability of financing for the Company’s commercial operations and/or research and development projects, or the availability of financing on reasonable terms; results of current and future clinical trials; uncertainties associated with acceptance and demand for new products and market competition. The above list of material factors and assumptions is not exhaustive. The Company undertakes no obligation to publicly update or otherwise revise any forward-looking statements or the foregoing list of factors, except as required by applicable law. Additional discussion of risks and uncertainties relating to the Company and its business can be found in the Company’s other filings with applicable Canadian securities regulators or the United States Securities and Exchange Commission, and in the “Risk Factors” section of his Form 20F for the year ended December 31, 2020.


Show original content:

SOURCE Medicine Inc.


Comments are closed.